A group of successful Bristol-based entrepreneurs has invested £192,500 into a research and development project in the city that is searching for faster diagnosis and treatment of Sepsis, which is the number one cause of death worldwide.  Sixteen members of Bristol Private Equity Club have backed GenomeKey, which is carrying out the pioneering research programme in Bristol. The investment will enable GenomeKey to leverage additional grant funding.